Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Phagenesis Ltd.
With the sizeable investment, Nestlé Health Sciences also gets a three-month right of first negotiation for licensing or partnering to develop any Aimmune candidates, including Phase III AR101 for peanut allergy.
September M&A deals picked up after a quiet summer with 23 M&A deals recorded, the busiest month of the year so far, which included two major deals closing at $4bn.
InSightec, TriVascular and NicOx are among firms with notable recent product approvals or launches.
This Month's Profile Group: Artificial Retinal Devices Help The Blind To See, features profiles of 2C Tech Corp., LambdaVision and Nano Retina. Plus these Start-Ups Across Health Care: Adenovir Pharma, Akrivis Technologies, Emboline and Phagenesis.
- Medical Devices